Bulevirtide: Whose Treatment Clock Was Running?
Editorial inference: understanding the terminated registry requires an account of treatment exposure across its two cohort pathways.
THE HIVEPROSPECT WEEKLY
Good stories. Better questions.
Drug discoveries, difficult failures and the business decisions between them.
SN514-066b: Reading the Pause and the Protocol
Inference: the useful question is what the experiment could establish, and which answers still require patient results.
Bextra Was More Potent Than Celebrex. So Why Did It Vanish?
More potent in a recombinant enzyme assay does not mean better for patients. The safety record explains why that distinction matters.